184 results about "TG - Triglyceride" patented technology

The invention relates to the technical field of genetic engineering, in particular to a recombinant vector, an expression plasmid, a recombinant schizochytrium limacinum mutant and a method for increasing the DHA content of microorganisms. The LIP1 gene for coding lipase in the microbial lipid droplet protein is knocked out through a homologous recombination technology, and the production of lipase in the microbial lipid droplet can be effectively inhibited, so that the hydrolysis process of triglyceride of polyunsaturated fatty acid stored in the lipid droplet to glycerol and free fatty acid in the later stage of microbial culture is blocked, and DHA is prevented from being lost from a TAG repository; experimental verification shows that in microorganisms represented by schizochytrium limacinum, the DHA content can be increased by 21.8% compared with that of a wild type, the yield and purity of DHA are increased, the stability of the microbial fermentation process is guaranteed, and application and popularization are facilitated.

The invention relates to a diacylglycerol acyltransferase capable of synthesizing triglyceride as well as a coding gene and application of the diacylglycerol acyltransferase, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the diacylglycerol acyltransferase is as shown in SEQ ID NO.1, and the amino acid sequence of the diacylglycerol acyltransferase is as shown in SEQ ID NO.2. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

The invention discloses a composition containing achillea millefolium extract, which is prepared from the following ingredients in percentage by weight: 45 to 55 percent of glycerol, 4 to 6 percent of hydrogenated lecithin, 3 to 5 percent of caprylic / capric triglyceride, 1 to 3 percent of 1, 2-hexanediol, 0.8 to 1.2 percent of achillea millefolium extract, 0.4 to 0.6 percent of ergothioneine and the balance of water. Through precise compounding of the achillea millefolium extract and the ergothioneine, the dual effects of anti-inflammation and skin repair are achieved, flavonoid and organic acid components in the achillea millefolium extract can effectively inhibit release of inflammatory mediators such as IL-6 and TNF-alpha, and sensitive symptoms such as red and swollen and pruritus are relieved.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

Methods improve cognitive functioning, for example, at least one of episodic memory, executive function, or language skills; supporting memory and / or recall; providing energy and / or ketones to the brain; and / or preventing and / or treating mild cognitive impairment (MCI) in an individual. A composition comprising medium chain triglycerides (MCTs) can be administered to the individual in a daily dosage providing from about 15 g to about 45 g MCTs. The MCTs can include from about 51 wt % to about 90 wt % of octanoic acid. The daily dose can be provided in at least two servings, for example, 2 or 3 servings. Each serving can provide about 15 g MCTs and can include octanoic acid and decanoic acid in a weight ratio of, for example, about 60:about 40. The individual can be 65 years or older and / or have mild cognitive impairment (MCI).

The invention relates to euphausia superba-derived diacylglycerol acyltransferase as well as a coding gene and application thereof, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the enzyme is as shown in SEQ ID NO.1, and the amino acid sequence of the enzyme is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the euphausia superba-derived diacylglycerol acyltransferase. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

The invention discloses an application of an ATGL inhibitor NG-497 in treatment of lung cancer / lung cancer metastasis. Researches prove that NG-497 can reduce the cell membrane fluidity and reduce the resistance of lung adenocarcinoma cells to fluid shear force by inhibiting decomposition of triglyceride, so that transfer of the lung adenocarcinoma cells is inhibited. The invention provides a potential new medicine and a new therapeutic target for lung cancer treatment or clinical treatment of lung cancer metastasis.

The invention provides an application of ginseng oil body in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of ginseng seed oil. The detection shows that the oil core structure of the ginseng oil body mainly consists of oleic acid and linoleic acid, and is different from the triglyceride core of the oil body obtained from the existing oil crops. Through lipidomics detection and analysis, the phospholipid monomolecular layer has 335 phospholipids (positive ion mode) and 269 phospholipids (negative ion mode). Through proteomics detection and analysis, 24 kinds of Panax proteins are identified. The condition that the oil core of the ginseng oil body contains protopanaxatriol (PPT) is identified through high performance liquid chromatography-high resolution mass spectrometry. In-vitro detection shows that the ginseng oil body has anti-inflammatory and anti-oxidation effects.

Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10wt% and 50wt% polar lipids and between 45wt% and 60wt% fatty acids, wherein the fatty acids comprise more than 10wt% of eicosapentaenoic acid (EPA) as triglyceride conjugates and / or diglyceride conjugates, and less than 15wt% EPA as free fatty acids. EPA level may reach up to 90wt%, and the botanical extract may be fluid at room temperature. Growth conditions are configured, adjusted and monitored to promote EPA formation in the cell vacuoles, resulting in a high proportion of EPA as tri / di-glyceride conjugates, as well as in a high concentration of Ω-3 fatty acids, which merely requires gentle extraction procedures to reach the final products, thereby maintaining the biochemical of the compounds without excessive modifications.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

An apparatus for measuring a triglyceride level includes: a sensor including: a plurality of peripheral light sources disposed at a periphery thereof, the plurality of peripheral light sources being configured to emit light toward an object, and a plurality of detectors each disposed at predetermined distances from the respective peripheral light sources of the plurality of peripheral light sources, the plurality of detectors being configured to detect optical signals reflected from or scattered by the object. The apparatus also includes a processor configured to selectively drive the plurality of peripheral light sources to obtain features based on the detected optical signals, and to measure the triglyceride level based on the obtained features.

The application discloses a preparation method of medium and long chain fatty acid triglyceride, and belongs to the technical field of oil deep processing. Firstly, plant oil and medium chain fatty acid triglyceride are used as substrates, a low eutectic solvent is used as a reaction medium, and an ester exchange reaction is carried out under the catalysis of immobilized lipase; after the reaction is completed, centrifugal treatment is carried out, and the low eutectic solvent, the immobilized lipase and the reaction product are recovered respectively; the recovered low eutectic solvent and the immobilized lipase are used for the next batch of reaction, and the recovered upper oil phase is the reaction product. The application uses immobilized lipase to catalyze ester exchange to prepare medium and long chain fatty acid triglyceride in a low eutectic system, the substrate conversion rate and the product generation amount are high, the product separation is easy, further separation and purification are not needed, the low eutectic solvent is green, environment-friendly and reusable, and the method has good ecological, economic benefits and industrialization application prospects.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention belongs to the field of pharmaceutical preparations, and provides an assembly material for indissolvable active transdermal mucosal drug delivery and a preparation method thereof. According to the invention, lipid cubic-phase nanoparticles composed of glyceryl monooleate, cholesterol, glycerol dioleate and caprylic / capric triglyceride are adopted, the design of DSPE-PEG2000 surface stability and ion coordinated regulation is combined, and high drug loading capacity and nanoscale particle size control are realized through a continuous process of melting, hydration, high-pressure homogenization and cubic-phase curing surface treatment. The preparation method solves the technical problems that high loading capacity of insoluble active ingredients and long-term colloidal stability are difficult to consider, cubic phase structure stability and surface charge controllability are contradictory in a tissue-friendly environment, and high drug loading capacity and devitrification prevention are difficult to couple under a low-temperature processing window, and has wide application value in the field of transdermal and mucosal local drug delivery.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

Provided herein are compositions and methods for modifying the human gene, APOC3. Such compositions and methods may result in the reduction of the protein, apolipoprotein C3 (apoC-III) when administered to a human subject. Compositions and methods provided herein may comprise a CRISPR-associated (Cas) protein or uses thereof. Compositions and methods of the present disclosure may be useful for treatment of APOC3 associated conditions, including persistent chylomicronemia, familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG).

This invention belongs to the field of biomedicine, specifically relating to siRNA targeting the angiopoietin-like protein 3 gene and its applications. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence; or a sense strand of 19 nucleotides and an antisense strand of 21 nucleotides with overhanging ends. The siRNA of this invention can comprehensively lower blood lipids, and has good lipid-lowering effects on triglycerides and LDL-C, helping to significantly reduce the risk of atherosclerosis and cardiovascular disease.

Provided herein are ultrasound couplants comprising a triglyceride and a phospholipid and methods of ultrasound imaging a subject using the same. The ultrasound imaging may be invasive ultrasound imaging. Also provided herein are methods of making ultrasonic couplants and methods of formulating ultrasonic couplants.

The invention relates to a composition and method to increase survival of fish following catch-and-release events. The composition comprises an energy substrate and a hydrocolloid. The composition may comprise an application-safe buffer. The energy substrate may be a glycolysis metabolite, a Krebs cycle metabolite, an amino acid, a nitric oxide donor, a triglyceride, and mixtures thereof. The hydrocolloid may be a polysaccharide. The composition may include an oxygenated substrate, a trophic hormone, a stress reducing additive, a chelating agent, an antimicrobial preservative, and a color additive, and mixtures thereof. The method comprises after catching the fish, applying the composition to the fish and releasing the fish back into the wild. The composition may alternatively be mixed with a flotant or a cured polymer in the shape of a lure such that composition may be dispersed onto the oxygen exchange tissue of the fish when it is caught.

The invention relates to a light and thin moisturizing lip cream and a preparation method thereof, and belongs to the technical field of cosmetics. The light and thin moistening type lip cream is prepared from the following raw materials: meadowfoam seed oil, ceramide NP, lecithin, caprylic acid / capric triglyceride, a dendrobium officinale-tremella-glucan compound, tetrahydromethylpyrimidine carboxylic acid, 1, 3-propylene glycol, inulin, a cooling agent WS-23, vitamin E, capryloyl hydroximic acid, ethylhexylglycerin and deionized water. The prepared lip cream provides bionic barrier repair by virtue of ceramide NP wrapped by nano-liposome, has strong water locking effect of a dendrobium officinale-tremella-glucan compound, and is compounded with other components such as meadowfoam seed oil, so that multiple moisturizing repair is provided under the condition that the texture is kept light and thin.

The objective is to provide an animal pest control device that prevents deformation of the container body and leakage of the pesticide, even when the container body is significantly distorted, and when alcohol or medium-chain triglyceride is used as the solvent for the pesticide. [Solution] The problem could be solved by a pest control device for animals, which comprises a container 1 made of polyolefin resin, having an active ingredient for pest control, a solvent containing alcohol or medium-chain triglyceride, a cut-off piece 11 to be cut off when used, a nozzle part 13 connected to the cut-off piece via a constricted part 12, a shoulder part 14 extending from the nozzle part and inclined at a larger angle than the nozzle part, and a container body part 16 extending from the shoulder part and sealed at a sealing part 15, wherein the length of the container body part is 0.5 to 4.0 times the diameter at the boundary between the shoulder part and the container body part or the length of the longest diagonal.

The application belongs to the technical field of biological medicine, and particularly relates to an adjuvant influenza vaccine and a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS buffer solution; the adjuvant is prepared by using mixed oil and an auxiliary agent, the mixed oil comprises squalene, medium-chain triglyceride and alpha-tocopherol; and the auxiliary agent comprises sorbitan trioleate Span-85, Tween 80 and vitamin E succinate polyethylene glycol ester. The adjuvant influenza vaccine prepared by the application has good immunization effect, and can especially improve the overall effect of a tetravalent adjuvant influenza vaccine on four viruses.

The invention discloses a platelet antibody detection kit and application thereof. Belongs to the technical field of detection kits. The kit comprises a microcolumn gel card, an enzyme-labeled secondary antibody, an enzyme-labeled secondary antibody diluent, a 20x washing solution, a developing solution, a fresh platelet treatment solution, a platelet buffer solution, a platelet preparation solution, a freeze-dried platelet reconstitution fluid, freeze-dried platelets and a negative control. The platelet antibody detection kit disclosed by the invention has the beneficial effects that the platelet antibody detection kit disclosed by the invention enables cross-matching of platelets to be possible; according to the invention, a micro-column gel immunoassay technology is combined with an enzyme immunolabeling technology, so that the limitation that only agglutination reaction can be carried out in a micro-column gel method is solved; according to the reaction card washing equipment disclosed by the invention, semi-automatic operation of micro-column gel method detection is realized; in the plasma, triglyceride is less than or equal to 5mg / mL, bilirubin is less than or equal to 20mg / dL, and hemoglobin is less than or equal to 5mg / mL, so that the result is not influenced; the kit has the advantages of good stability, long effective period, high sensitivity, strong specificity and simple operation.

This specification provides ultrasound coupling agents and methods for using them in ultrasound imaging of a target. The ultrasound imaging may be invasive ultrasound imaging. Methods for preparing ultrasound coupling agents and methods for formulating ultrasound coupling agents are also provided herein. An aqueous ultrasound coupling agent comprising a) at least one triglyceride in about 60.0 to about 80.0 g / L, b) at least one phospholipid in about 3.2 to about 5.2 g / L, c) water, d) pH buffer, and e) glycerol is described herein, wherein the ultrasound coupling agent has an attenuation constant of about 0.15 dB / (MHz*cm) to about 0.60 dB / (MHz*cm) or about 0.002 to about 1.0 dB / (MHz*cm).

The invention relates to an anti-aging composition, and belongs to the field of medicines and health-care product preparations. The composition is a microcapsule assembled by a water-soluble wall material, a first core material, a fat-soluble wall material and a second core material which are sequentially coated from outside to inside, and the first core material comprises beta-nicotinamide mononucleotide (NMN), nicotinamide ribose (NR), ergothioneine and trimethylglycine (TMG); the second core material comprises resveratrol, curcumin, pyrroloquinoline quinone (PQQ) and spermidine, and is dissolved in medium chain triglyceride (MCT oil) containing an antioxidant tocopherol. According to the dosage form, physical isolation and differentiated release of water-soluble and fat-soluble components are realized, and the problems of incompatibility among the components, poor stability, low bioavailability and the like are solved. Through the multi-target synergistic effect, the composition can effectively improve the NAD + level and enhance the mitochondrial function so as to improve the skin state and delay senescence.

The invention provides an antiviral drug screening marker and application of a microsome triglyceride transfer protein inhibitor in preparation of an antiviral drug, and finds new application of the microsome triglyceride transfer protein inhibitor in antiviral infection for the first time compared with the prior art. Experiments prove that the expression level of the microsome triglyceride transfer protein in the process of infecting cells with vesicular stomatitis virus is remarkably increased, and the microsome triglyceride transfer protein is used as an antiviral drug screening marker. The invention provides a new target spot for the treatment of virus infection, and the lomitapide as a marketed drug has verified safety, can be quickly transformed and applied, and has a wide application prospect. The invention has broad spectrum potential of targeting host factors or being effective to various viruses (such as coronavirus and influenza virus).